TARO News and Press, Taro Pharmaceutical Industries Ltd. From 10/28/20

Taro Pharmaceutical (TARO): Q3 GAAP EPS of $1.18 beats by $0.41.Revenue of $142.84M (-11.2% Y/Y) beats by $17.5M.Press Release For further details see: Taro Pharmaceutical EPS beats by $0.41, beats on revenue

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2020. Quarter ended September 30, 2020 Highlights ─ compared to September 30,...

Earnings Call on Thursday, October 29th at 8:00 am ET Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2020, on Wednesday, October 28, 2020. The Company will...

Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate. The Summers Value Fund LP declined by 1.2% net during the first nine months of 2020, outpacing the...

Taro Pharmaceutical ([[TARO]] -0.5%) has announced the launch of deferiprone, a generic version of Chiesi's Ferriprox, an iron chelator indicated for transfusional iron overload due to thalassemia syndromes, when current chelation therapy is not su...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or “the Company”) today announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndrom...

Taro Pharmaceutical (NYSE: TARO ) : Q1 EPS of -$11.37 may not be comparable to consensus of $1.16. More news on: Taro Pharmaceutical Industries Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

Quarter reflects One-Time Charge for Global Resolution with DOJ Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today provided unaudited financial results for the quarter ended June 30, 2020. Quarter ended June 30, 2020 Highlights - compared to Quarter en...

Taro Pharmaceuticals (NYSE: TARO ) says it agrees to pay ~$205M to settle allegations by the Department of Justice that it conspired to fix prices and rig bids for generic drugs. More news on: Taro Pharmaceutical Industries Ltd., Healthcare stocks news, Read more ...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that its wholly-owned subsidiary, Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”), has resolved all cases involving the Company in connection with the multi-year investigations by the Depa...